Abbott Q2 sales rise 13.0% to $12.6 billion; raises 2026 adjusted EPS guidance
Abbott reported second-quarter 2026 net sales of $12.6 billion, up 13.0% from a year earlier, with comparable sales growth of 4.8%. It raised its full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60, but GAAP diluted EPS fell to $0.53 from $1.01 after large specified-item charges, including $658 million of intangible amortization.
Key points
- Q2 2026 net sales were $12.593 billion, up 13.0% reported and 4.8% comparable; Diagnostics rose 42.3% reported, boosted by the Exact Sciences acquisition completed March 23, 2026.
- Adjusted diluted EPS was $1.31, up from $1.26; GAAP diluted EPS was $0.53, down from $1.01, and GAAP net earnings were $928 million versus $1.779 billion.
- Full-year 2026 adjusted diluted EPS guidance was raised to $5.45 to $5.60 from $5.38 to $5.58; comparable sales growth guidance of 6.5% to 7.5% was reaffirmed.
- Abbott returned $2.1 billion to shareholders in the quarter via dividends and share repurchases, and declared a $0.63 quarterly dividend payable Aug. 17, 2026.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.